Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMHN zongertinib HER2 NSCLC Coverage Update | OpenP…
    Ask Trek AI about this page
    CurrentmhnPolicy CP.PHAR.750

    Zongertinib (Hernexeos) — Coverage Criteria for HER2‑mutant NSCLC

    Customize your policy alerts

    Sign up for mhn Policy CP.PHAR.750 alerts

    Get alerted when Policy CP.PHAR.750 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity and prior authorization criteria for zongertinib (Hernexeos) for adults with unresectable or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) activating mutations; applies to Centene-affiliated health plans including Commercial, HIM, and Medicaid.

    Policy Summary
    Payermhn
    PolicyZongertinib (Hernexeos) — Coverage Criteria for HER2‑mutant NSCLC
    Policy CodePolicy CP.PHAR.750
    Change TypeOperational update to align with expanded FDA prescribing information
    Effective DateDec 1, 2025
    Next Review Date
    Key ActionSubmit prior authorization with documentation confirming diagnosis, oncologist involvement, age ≥18, single‑agent use, HER2 activating mutation, and weight‑based dosing limits.
    SourceLink
    POLICY UPDATE CHANGES

    Removed requirement for prior systemic therapy in FDA approved indications and removed 'failure of a prior systemic therapy' requirement in initial approval criteria to reflect expanded indication per prescribing information.

    ≥18Minimum age for therapy
    12 mo

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Approval duration
    120 / 180 mgDosing options
    60 mgProduct strength
    AcceleratedRegulatory status

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met

    Initial NSCLC Criteria: 1. Diagnosis of unresectable, recurrent, advanced, or metastatic non-small cell lung cancer (NSCLC); 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Prescribed as a single agent; 5. Disease harbors activating HER2 (ERBB2) mutations; 6. For Hernexeos requests, member must use zongertinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 7. Request meets dosing requirements: either (a) dose does not exceed weight-based limits (see dosing limits) OR (b) dose is supported by practice guidelines or peer-reviewed literature with prescriber-submitted evidence;

    Prescribed regimen must be FDA‑approved or recommended by NCCN.

    Dosing Limits / Off-label Dosing Exception

    Dosing criteria: Either (a) dose does not exceed weight-based limits: i) For body weight < 90 kg: 120 mg PO once daily; ii) For body weight ≥ 90 kg: 180 mg PO once daily (maximum 180 mg/day) OR (b) dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use with prescriber submission of supporting evidence.120 mg or 180 mg per day

    Prescribed regimen must be FDA‑approved or recommended by NCCN.

    Continuation Therapy

    Covered when ALL of the following are met

    Continued NSCLC Criteria: 1. Member is currently receiving medication via the Centene benefit or documentation supports member has received Hernexeos for a covered indication for at least 30 days; 2. Member is responding positively to therapy; 3. For Hernexeos requests, member must use zongertinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 4. If request is for a dose increase, the new dose must either (a) not exceed weight-based limits (120 mg/day for <90 kg; 180 mg/day for ≥90 kg) or (b) be supported by practice guidelines or peer‑reviewed literature with prescriber-submitted evidence.30 days

    Prescribed regimen must be FDA‑approved or recommended by NCCN.

    Non–FDA approved indications that are not specifically addressed in this policy are not authorized for coverage unless there is sufficient documentation of efficacy and safety consistent with the referenced off‑label use policies (see CP.CPA.09, HIM.PA.154, CP.PMN.53) or applicable evidence of coverage documents.

    Coverage is not authorized for non‑FDA approved indications that lack adequate supporting documentation per the referenced off‑label use policies. Requests for off‑label use must meet the documentation standards outlined in CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP.PMN.53 (Medicaid) to be considered.

    Coding

    No explicit CPT/HCPCS/ICD codes listedmixed
    No codes listed
    inv-07: Maximum Dose — 180 mg/day
    Maximum permitted daily dose180 mg/day
    Source dosing statementNSCLC, Maximum Dose = 180 mg/day (V. Dosage and Administration)
    Context in initial criteriaFor body weight ≥ 90 kg: 180 mg (3 tablets) per day (Initial Approval Criteria)

    Provider Actions / Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required before Hernexeos (Hernexeos) will be approved. The provider must document the diagnosis, oncologist involvement, member age, single‑agent use, presence of an activating HER2 (ERBB2) mutation, dosing that does not exceed policy limits (or justification per guidelines/literature), and that the prescribed regimen is FDA‑approved or recommended by NCCN. For initial and continued therapy requests, approval duration is 12 months.

    • Prescribed by or in consultation with an oncologist
    • Age ≥ 18 years
    • Single‑agent use
    • Activating HER2 (ERBB2) mutation documented
    • Dose limits: <90 kg = 120 mg/day (2 tablets); ≥90 kg = 180 mg/day (3 tablets) unless higher dose supported by practice guidelines or peer‑reviewed literature
    • Prescribed regimen must be FDA‑approved or recommended by NCCN
    Denial Risk

    Background

    Zongertinib (Hernexeos) is a kinase inhibitor indicated under accelerated approval for adult patients with unresectable or metastatic nonsquamous non‑small cell lung cancer harboring HER2 (ERBB2) tyrosine kinase domain activating mutations. Continued approval is contingent on verification of clinical benefit in confirmatory trials; prescribing and coverage decisions for non‑FDA indications must follow the off‑label documentation requirements referenced in this policy.

    Definitions

    inv-13: HER2 (ERBB2) activating mutations — definition of tumor mutations detected by an FDA-approved test
    DefinitionTumors with HER2 (ERBB2) tyrosine kinase domain activating mutations detected by an FDA-approved test
    Indication linkageThese activating mutations confer eligibility for zongertinib (Hernexeos) in unresectable or metastatic nonsquamous NSCLC
    Regulatory noteIndication approved under accelerated approval; continued approval contingent on confirmatory trial verification

    Initial Therapy Criteria

    Initial Therapy

    Covered when ALL of the following are met

    Initial Therapy — NSCLC: 1. Diagnosis of unresectable, recurrent, advanced, or metastatic nonsquamous NSCLC; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Prescribed as a single agent; 5. Tumor has activating HER2 (ERBB2) mutations; 6. For Hernexeos requests, member must use zongertinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 7. Dose does not exceed weight-based limits or is supported by practice guidelines/peer‑reviewed literature with prescriber evidence (see dosing limits).

    Prescribed regimen must be FDA‑approved or recommended by NCCN. Approval duration: 12 months.

    Continuation Criteria

    Continued Therapy

    Covered when ALL of the following are met

    Continued Therapy — NSCLC: 1. Currently receiving medication via Centene benefit, or documentation supports member has received Hernexeos for a covered indication for at least 30 days; 2. Member is responding positively to therapy; 3. For Hernexeos requests, member must use zongertinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 4. If a dose increase is requested, the new dose must not exceed weight-based limits or must be supported by practice guidelines/peer‑reviewed literature with prescriber-submitted evidence.30 days

    Prescribed regimen must be FDA‑approved or recommended by NCCN. Approval duration: 12 months.

    Step Therapy / Product Preference

    StepRequirement
    {"text":"1","status":""}|{"text":"For Hernexeos requests, member must use zongertinib if available unless contraindicated or clinically significant adverse effects are experienced.","status":""}

    Quantity Limits

    inv-17: Zongertinib (Hernexeos) — 120 mg or 180 mg
    Standard daily dosing options120 mg once daily for body weight < 90 kg; 180 mg once daily for body weight ≥ 90 kg
    Tablet strengthEach 60 mg tablet; 120 mg = 2 tablets, 180 mg = 3 tablets
    Approval duration and useDosing options specified in Initial Approval Criteria and Dosage & Administration for NSCLC

    Site of Care

    Note

    Site of care: office — standard PA/documentation rules apply

    No specific site‑of‑care restrictions are listed; standard prior authorization and documentation requirements apply for office-administered requests.

    • Follow normal prior authorization submission processes for office settings
    • Ensure required clinical documentation accompanies the PA request
    Policy Summary
    Payermhn
    PolicyZongertinib (Hernexeos) — Coverage Criteria for HER2‑mutant NSCLC
    Policy CodePolicy CP.PHAR.750
    Change TypeOperational update to align with expanded FDA prescribing information
    Effective DateDec 1, 2025
    Next Review Date
    Key ActionSubmit prior authorization with documentation confirming diagnosis, oncologist involvement, age ≥18, single‑agent use, HER2 activating mutation, and weight‑based dosing limits.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions / RequirementsBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep Therapy / Product PreferenceQuantity LimitsSite of Care

    Non‑FDA Indications Risk

    Requests for non‑FDA approved (off‑label) indications that are not addressed in this policy may be denied unless the provider submits sufficient documentation demonstrating efficacy and safety consistent with the payer's off‑label use policies (CP.CPA.09 for commercial, HIM.PA.154 for HIX, CP.PMN.53 for Medicaid) or other applicable evidence of coverage documents.

    • Non‑FDA indications require supporting evidence per relevant off‑label policies: CP.CPA.09, HIM.PA.154, CP.PMN.53
    Documentation Required

    Required Documentation

    Provider must submit documentation (such as office chart notes, recent pathology or molecular testing reports confirming HER2 (ERBB2) activating mutation, prior treatment history, weight for dosing, evidence of response for continuation requests, and any supporting literature if dosing exceeds policy limits) to support that the member meets all applicable criteria.

    • Office chart notes and clinical history
    • Pathology/molecular testing confirming HER2 (ERBB2) activating mutation
    • Documentation of current therapy and response (for continuation)
    • Member weight to determine dosing tier
    • Supporting practice guidelines or peer‑reviewed literature if dose exceeds listed limits
    Prior Authorization

    Preferred Product Requirement

    When applicable, the policy requires use of zongertinib for members prior to approving Hernexeos when zongertinib is available and not contraindicated. If zongertinib is contraindicated or clinically not tolerated, document the contraindication or adverse effects.

    • Member must use zongertinib first if available unless contraindicated or clinically significant adverse effects
    • If contraindicated/intolerant, provide documentation of the reason